IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT January 31, 2018Investors’ Rights Agreement • April 4th, 2019 • Ideaya Biosciences, Inc. • Pharmaceutical preparations • California
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of January 31, 2018, by and among Ideaya Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”).
EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • April 4th, 2019 • Ideaya Biosciences, Inc. • Pharmaceutical preparations • Manchester
January 27, 2017Ideaya Biosciences, Inc. • April 4th, 2019 • Pharmaceutical preparations
IDEAYA BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • April 4th, 2019 • Ideaya Biosciences, Inc. • Pharmaceutical preparations • California
Ideaya Biosciences, Inc. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Option Grant Notice and the Stock Option Agreement.
LICENSE AGREEMENTLicense Agreement • April 4th, 2019 • Ideaya Biosciences, Inc. • Pharmaceutical preparations • New York
This License Agreement (“Agreement”), made as of September 19, 2018 (“Effective Date”), is by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and IDEAYA Biosciences, Inc., a Delaware corporation located at 7000 Shoreline Court, Suite 350 South, San Francisco, CA 94080 USA (“Ideaya”). Novartis and Ideaya are each referred to individually as a “Party” and together as the “Parties.”
